Nordic Bioscience launches novel Endotrophin assay
HERLEV, Denmark, May 16, 2025 /CNW/ -- Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin signaling hormone—qualified in the CAP/CLIA certified Nordic Bioscience laboratory. When integrated with the company's existing product line, the biomarker assay demonstrated prognostic utility in fibrosis and cancer studies 1.
NordicEndotrophin™ joins nordicPRO-C6™ and nordicPRO-C3™ (in-house versions of the FDA-supported PRO-C6 and CE approved PRO-C3 assays) to deliver a one-stop solution for assessing the fibro-inflammatory axis in chronic diseases, including cardiovascular, metabolic, renal and more. Following PRO-C3's recent deployment on Roche IVD platforms, the new Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring.
Endotrophin was first identified in 2012 as a collagen-derived hormone released from type VI collagen. Type VI collagen is a contributor to fibroblast activation and driver of fibrosis across organs—inflammatory processes that underlie roughly 40 percent of deaths in Western countries 2. Obesity exacerbates this by activating fibroblasts in the liver, kidney and heart. Across a range of chronic diseases, patients with a two-fold increase of circulating Endotrophin levels increased risk of mortality by 100% 1,2. Quantifying Endotrophin enables researchers to connect wound healing and fibrotic progression to patient outcomes, supporting precision-medicine approaches that pharmacodynamically modulate this dangerous hormone.
Whereas PRO-C6, Nordic Bioscience's first hand-held ELISA assay measuring the formation of the total pool of type VI collagen (a3 chain encompassing 12 Von Willebrand binding domains), a collagen responsible for binding of platelets that cause fibroblast activation and would healing, nordicEndotrophin™ specifically measures the intact 77-amino-acid hormone. This specificity means additional risk stratification and prognostic value that complement PRO-C6's fibrosis-driven pharmacodynamic insights 1.
" Endotrophin is a significant prognostic biomarker to emerge," said CEO Dr. Morten Karsdal. " Evidenced in a study of HFpEF patients, Endotrophin and PRO-C6 outperformed NT-proBNP in HFpEF for mortality and hospitalization risk 3. Together with PRO-C3, quantifying this fibro-inflammatory hormone will refine patient stratification and treatment monitoring across obesity, fibrotic diseases, and autoimmune endotypes."
Offered in Nordic Bioscience's CAP/CLIA-certified laboratory in Herlev, Denmark, the nordicEndotrophin™ high-precision sandwich assay is available on fully automated, high-accuracy, high-throughput platforms. To accelerate drug fibro-inflammatory profiling, clients considering nordicEndotrophin™ are invited to co-measure nordicPRO-C3™ and nordicPRO-C6™. Together, these assays facilitate precise risk stratification, dose selection, patient enrichment, proof-of-mechanism and treatment monitoring in anti-fibrotic and oncology trials 2.
About Nordic Bioscience
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at
[2] https://pubmed.ncbi.nlm.nih.gov/38091968/
[3] https://pubmed.ncbi.nlm.nih.gov/37645406/
SOURCE Nordic Bioscience
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
Over 4,400 Riders Embark on Ride to Conquer Cancer, Canada's Largest Athletic Fundraiser, Raising Over $20.61 Million for Life-Saving Research
TORONTO, June 7, 2025 /CNW/ - The 18 th annual The Princess Margaret Ride to Conquer Cancer, presented by Johnson & Johnson, commenced this morning with over 4,000 riders departing from Sherway Gardens, Toronto in a group peloton. At the same time, more than 400 riders began their journey from the Niagara-on-the-Lake start line. Both groups will converge at McMaster University in Hamilton for overnight camp later today. This year's Ride sets a record for funds raised with $20.61 million, surpassing the previous record of $20.6 million set in 2024. United in their mission to create a world free from the fear of cancer, all riders are taking on the two-day, 200+ km journey to Niagara-on-the-Lake in support of Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres. "Cancer remains one of the greatest global health threats of our time," said Dr. Miyo Yamashita, President and CEO of The Princess Margaret Cancer Foundation. "Yet, through the unwavering dedication of our Ride community— riders, donors, supporters and volunteers, together we are transforming the way cancer is understood, prevented, diagnosed and treated in Canada and around the world." Among the riders was Dana Fox, who knows firsthand the importance of this cause. Diagnosed with cholangiocarcinoma, a rare and aggressive cancer, Dana is currently undergoing treatment at The Princess Margaret but is committed to completing the 200km journey. "You are fueling hope, you are funding discovery, and you are changing lives," Dana rallied to the crowd in his opening ceremony's patient remarks. "This isn't just a fundraiser. This is a movement." Participants have collectively raised an astounding $20.61 million this year, bringing The Ride's all-time fundraising total to more than $320.61 million since its inception in 2008. These funds directly support life-saving cancer research and patient care at Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres. As The Ride's 2025 Honourary Chairs, Nicholas and Lia Fidei said, "After witnessing some of the success stories and meeting cancer patients who have overcome cancer, there is no doubt in our minds how much we need to support The Ride and the advancements in cancer research that The Princess Margaret is renowned for." Nicholas, President of Treasure Hill and President of the Nicholas Fidei Foundation, and this year's top individual fundraiser also added, "No other fundraising event that I have participated in has inspired me to greater achievements." All riders are now making their way to Hamilton, where they'll be welcomed by cheering family and friends, enjoy a hot meal at camp ceremonies and spend the night at McMaster University. On Day 2, they'll continue their journey to the finish line at Peller Estates Winery in Niagara-on-the-Lake. For more information, to donate or to register for the 2026 Ride to Conquer Cancer, please visit The Princess Margaret Cancer Foundation is Canada's largest cancer charity. We're dedicated to raising funds for Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres, known for its breakthrough discoveries that transform patient outcomes. Together, our work benefits cancer patients everywhere in our mission to create a world free from the fear of cancer. Through philanthropy, fundraising events, and our world-leading lottery program, we're changing how the world understands, prevents, diagnoses, and treats cancer, benefitting patients at The Princess Margaret, throughout Canada, and around the world. SOURCE Princess Margaret Cancer Foundation
Cision Canada
a day ago
- Cision Canada
Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
TORONTO, June 6, 2025 /CNW/ - Sunday, June 8, 2025 — National advocacy organization Obesity Matters will host the Your Health Matters Summit 2025 at the historic Old Mill Toronto, with virtual access available across Canada. This one-day, community-powered event is creating space for real stories, honest conversations, and stigma-free care — putting people, not just conditions, at the center of health and wellness. With the theme "Inspire Change. Build Connection. Advance Wellness.", the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support. "Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity," says Priti Chawla, Executive Director of Obesity Matters. "This summit is about rewriting the narrative — one story, one connection, one person at a time." Program highlights include: Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience Dr. Megha Poddar on hormone health across life stages Dr. Peter Selby facilitating a storytelling session with patient advocates Dr. David Macklin on Resilience… The Secret Skill to Success A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters. "We can't let outdated ideals or social media define what health looks like," says Dr. Sandy Van. "In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind." "For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment." — Sandra Elia, Chair, Obesity Matters
Cision Canada
a day ago
- Cision Canada
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy Français
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. "As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred." Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. "As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally." Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. "Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health." Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of Pharmacy The School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. SOURCE GlaxoSmithKline Inc.
